Efficacy Analysis of Tigecycline-based Therapy and Polymyxin B-based Therapy in ICU Infection

Study Overview
=================
Brief Summary
-----------------
The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin B admitted to the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from 2017 to 2021 were included. To analyze the therapeutic effect of tigecycline-based or polymyxin B-based antibiotic regimens and their effect on the prognosis of patients, and to conduct subgroup analysis.

Detailed Description
-----------------
The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin B admitted to the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from 2017 to 2021 were included. The four hospitals included the 1st-3th XiangYa Hospitals and Hunan Provincial People's Hospital. Organize the data.Patients with a course of treatment < 4 days and shedding were excluded.To analyze the therapeutic effect of tigecycline-based or polymyxin B-based antibiotic regimens and their effect on the prognosis of patients, and to conduct subgroup analysis. The chi-square test was used for the counting data, and the Mann-Whitney U test or Kruskal-Wallis H test was used for the measurement data. The significance value was adjusted by Bonferroni correction method for multiple tests, and the P was tested on both sides,P>0.05.

Official Title
-----------------
Efficacy Analysis of Tigecycline-based Therapy and Polymyxin B-based Therapy in ICU Infection

Conditions
-----------------
Tigecycline, Polymyxin B, Intensive Care Unit

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICU patients receiving tigecycline or polymyxin B treatment; Age 14-95, gender unlimited; there are clear infections and strains; The patient and/or his/her family agree to sign the informed consent voluntarily. Exclusion Criteria: Patients with treatment of less than 4 days; patients with abscission; Pregnant patients; Patients with age < 14 years or > 95 years.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hospital mortality rate | Patients die in hospital or abandon treatment due to poor prognosis in hospital after treatment of tigecycline or polymyxin B | up to hospital discharge or die in hospital, up to 48 weeks(estimation). | 
| 30d mortality rate | Patients die after treatment of tigecycline or polymyxin B | up to the 30th day of the treatment of tigecycline or polymyxin B | 
| Bacterial clearance rate | Bacterial clearance during treatment of tigecycline or polymyxin B | from the first day of the treatment of tigecycline or polymyxin B until to the end day, up to 8 weeks (estimation). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The length of hospital stay | The length of hospital stay,days | up to hospital discharge or die in hospital, up to 48 weeks (estimation). | 
| The length of ICU stay | The length of ICU stay | up to hospital discharge or die in hospital, up to 24 weeks (estimation). | 
| Hospitalization Cost | total Hospitalization Cost | up to hospital discharge or die in hospital, up to 48 weeks (estimation). | 
| serum creatinine | serum creatinine at the end day of the treatment of tigecycline or polymyxin B | at the end day of the treatment of tigecycline or polymyxin B, up to 8 weeks (estimation). | 
| MV days | the total days with mechanical ventilation | up to hospital discharge or die in hospital, up to 48 weeks (estimation). | 
| VA days | the total days with vasoactive agent | up to hospital discharge or die in hospital, up to 48 weeks (estimation). |